SLC5A2 and Hypoglycemia: The meta-analysis results showed no significant difference between the SGLT2-i plus metformin group and the metformin monotherapy in the incidence risk of hypoglycemia [RR = 1.44, 95%CI (0.89, 2.32), p = 0.13], or the risk of AEs of UTI [RR = 1.19, 95% CI (0.89, 1.58), p = 0.25], nor the risk of volume related AEs [RR = 1.86, 95% CI (0.59, 5.90), p = 0.29].